“A world-class automated insulin delivery system needs to be simple to use, rely on the most accurate CGM data available, and use a proven and trusted algorithm,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “We believe the combination of Tandem, Dexcom, and TypeZero technologies will deliver all three, and we are honored to be working together with them for this trial.”
"Our efforts with Tandem began with the display of CGM data on their t:slim G4 Pump and we are pleased to take this next step in the integration of our future products to support automated insulin delivery," said Steve Pacelli, EVP, Strategy & Corporate Development at Dexcom.
“The addition of Tandem’s innovative touchscreen pumps to the IDCL Trial is tremendous, and a great first step in their integration of our inControl algorithm into a future software update for the t:slim X2 Pump,” said Chad Rogers, Chief Executive Officer at TypeZero Technologies. “We look forward to bringing these solutions to patients in the upcoming IDCL trial and ultimately delivering a best-in-class automated insulin delivery solution to patients across the globe.”
The IDCL Trial is expected to enroll 240 adults with type 1 diabetes and is projected to start in late 2016. TypeZero’s technology includes a series of algorithms developed from initial research conducted at the University of Virginia. To date, this technology has been used in more than 28 clinical studies including more than 475 participants, with data referenced in a number of journal articles.
NEWS WILL BE released before EoY on clinical trial for this new product !!!!!!
Recent TNDM News
- Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union • Business Wire • 09/19/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 09:06:21 PM
- Tandem Diabetes Care Announces Upcoming Conference Participation • Business Wire • 08/26/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:00 AM
- Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall • Business Wire • 08/19/2024 10:30:00 PM
- Tandem Diabetes Care Provides Update on March 2024 Nationwide Recall of t:connect Mobile App for iOS Devices • Business Wire • 08/12/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:52:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:11:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:07:59 PM
- Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance • Business Wire • 08/01/2024 08:05:00 PM
- Tandem Diabetes Care Announces Upcoming Conference Presentation • Business Wire • 07/30/2024 08:05:00 PM
- Tandem Diabetes Care and Dexcom Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada • Business Wire • 07/29/2024 01:00:00 PM
- Tandem Diabetes Care et Dexcom annoncent que la pompe à insuline t:slim X2 compatible avec le système de SGC Dexcom G7 est autorisée à la vente par Santé Canada • Business Wire • 07/29/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:16:51 PM
- Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 • Business Wire • 07/11/2024 08:05:00 PM
- Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions • Business Wire • 06/22/2024 03:00:00 PM
- Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer • Business Wire • 06/20/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:31:22 PM
- Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions • Business Wire • 06/18/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:10:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 09:39:07 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM